<DOC>
	<DOCNO>NCT02954848</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety oral TAK-438 10 mg once-daily treatment non-erosive gastroesophageal reflux disease</brief_summary>
	<brief_title>Phase 3 Study TAK-438 ( 10 mg ) Treatment Non-Erosive Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>A phase 3 , randomize , double-blind , placebo-controlled , parallel-group , multicenter study conduct verify superiority TAK-438 ( TAK-438 10 mg , daily , 4 week ) placebo ( placebo , daily , 4 week ) patient non-erosive gastroesophageal reflux disease ( NERD ) . The study consist 1-week , single-blind run-in period 4-week , double-blind treatment period . The participant receive study drug ( TAK-438 placebo tablet ) 1-week single-blind run-in period . After run-in period , eligible participant randomize TAK-438 10 mg placebo treatment group 1:1 ratio . The randomized participant receive assign study drug ( TAK-438 10 mg tablet TAK-438 placebo tablet ) 4-week double-blind treatment period .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write informed consent form prior initiation study procedure . 3 . The participant NERD . 4 . The participant endoscopically confirm modify LA Classification Grade N M start runin period ( Visit 1 ) . To allow efficacy evaluation participant Grade N well Grade M , target number participant grade least 30 % total number participant . Enrollment patient either Grade N M end number enrol participant grade exceeds 332 , 70 % total planned number participant . 5 . The participant experience recurrent heartburn , least 2 day week last 3 week prior start runin period ( Visit 1 ) . 6 . The participant either male female outpatient minimum age 20 year time inform consent signing . However , participant hospitalize examination purpose also allow participate . 7 . A female participant childbearing potential agrees use routinely adequate contraception signing inform consent throughout duration study , 4 week last dose study drug . 8 . The participant 's compliance study drug good ( 75 % good ) runin period . 9 . The participant experience heartburn least 2 day last 1 week prior randomization . 10 . The participant appropriately provide patient 's diary require information runin period . 1 . The participant receive investigational compound within 84 day prior first dose study drug . 2 . The participant receive TAK438 previous clinical study therapeutic agent , except one experience receive TAK438 adjunct therapy H. pylorus eradication , enrol study . 3 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The participant donate least 400 mL blood within 90 day prior start runin period ( Visit 1 ) . 5 . Endoscopic examination enter study fails diagnose NERD within 84 day start runin period ( Visit 1 ) . 6 . The participant complication affect esophagus , include Barrett 's esophagus ( 3 cm , long segment Barrett 's esophagus [ LSBE ] ) , eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stenosis ; history radiation therapy cryotherapy esophagus ; caustic physiochemical trauma ( eg , esophageal sclerotherapy ) . However , participant Barrett 's mucosa ( le 3 cm , short segment Barrett 's esophagus [ SSBE ] ) Schatzki 's ring ( mucosal tissue ring line inferior esophageal sphincter ) permit participate . 7 . The participant history surgery treatment affect gastroesophageal reflux , include fundoplication mechanical dilatation esophageal stenosis ( except Schatzki 's ring ) , history gastric duodenal surgery ( except endoscopic removal benign polyp ) . 8 . The participant acute upper gastrointestinal bleeding gastric duodenal ulcer , characterize defective mucosa white coating , within 30 day prior start runin period ( Visit 1 ) . However , participant gastric duodenal erosion permit participate . 9 . The participant acute gastritis acute exacerbation chronic gastritis . 10 . The participant , history , ZollingerEllison syndrome gastric acid hypersecretion disorder . 11 . The participant , history chest pain due cardiac disease , chest pain suspectedly cause cardiac disease within 1 year prior start runin period ( Visit 1 ) . 12 . The participant concurrent upper gastrointestinal symptom severe heartburn . 13 . The participant depression . 14 . The participant , history , suspect functional upper gastrointestinal disorder , functional dyspepsia functional heartburn diagnose Rome IV criterion . 15 . The participant history hypersensitivity allergy TAK438 ( include formulation excipients ) . 16 . The participant history complication drug abuse ( define illicit drug use ) alcohol abuse within 1 year prior start runin period ( Visit 1 ) . 17 . The participant require excluded medication treatment . 18 . The female participant pregnant , lactating , intend become pregnant donate ova time inform consent sign 4 week last dose study drug . 19 . The participant serious neurological , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , endocrinological , hematologic disease . 20 . The participant need surgery require hospitalization course study , surgery require hospitalization schedule participant course study . 21 . The participant history malignancy treat malignancy within 5 year prior start runin period ( Visit 1 ) . However , participant recover completely cutaneous basal cell carcinoma cervical carcinoma situ permit participate . 22 . The participant acquire immunodeficiency syndrome ( AIDS ) hepatitis , human immunodeficiency virus ( HIV ) carrier , test positive hepatitis B virus surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody . However , participant test negative HCV antigen HCVRNA permit participate . 23 . The participant follow abnormal clinical laboratory test value start runin period ( Visit 1 ) : Creatinine &gt; 2 mg/dL . ALT AST &gt; ULN . Bilirubin ( Total bilirubin ) &gt; ULN .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>